Alessandro Bertolini

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2018 · 789 citations · Full text

Medicine, Oncology, Pharmacology +17

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

Luigi Celio, S. Frustaci, Angela Denaro et al. · Supportive Care in Cancer · 2010 · 100 citations · Full text

Medicine, Oncology, Pharmacology +17

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

Nicola Silvestris, Francesco Pantano, Toni Ibrahim et al. · PLoS ONE · 2013 · 67 citations · Full text

Medicine, Oncology, Surgery +15

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation

Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro et al. · Journal of Clinical Oncology · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +16